Evidence map›Paper›PMID 33469600›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial.

Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 5 countries.

Olha HolubovskaO.O. Bogomolets National Medical University, T. Shevchenko blvd., 13, Kyiv, Ukraine.
Denisa BojkovaInstitute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Stefano ElliIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, 20133 Milano, Italy.
Marco BechtelInstitute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
David BoltzIIT Research institute, 10 W 35th St, Chicago, IL 60616, United States.
Miguel MuzzioIIT Research institute, 10 W 35th St, Chicago, IL 60616, United States.
Xinjian PengIIT Research institute, 10 W 35th St, Chicago, IL 60616, United States.
Frederico SalaIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, 20133 Milano, Italy.
Cesare CosentinoIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, 20133 Milano, Italy.
Alla MironenkoL.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Department of respiratory and other viral infections, Amosova str 5a, 03083, Kyiv, Ukraine.
Jens MildePharmalog Institut für klinische Forschung GmbH, Ismaning, Germany.
Yuriy LebedPharmaxi LLC, Filatova Str., 10A, office 3/20, 01042, Kyiv, Ukraine.
Holger StammerPharmalog Institut für klinische Forschung GmbH, Ismaning, Germany.
Andrew GoyFarmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine.
Marco GuerriniIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, 20133 Milano, Italy.
Lutz MuellerDr. Regenold GmbH, Zöllinplatz 4, D-79410 Badenweiler, Germany.
Jindrich CinatlInstitute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Victor MargitichFarmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine.
Aartjan J W Te VelthuisDivision of Virology, Department of Pathology, Addenbrooke's Hospital, University of Cambridge, Hills Road, CB2 2QQ, United Kingdom.
Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni · ITGoethe University Frankfurt · DEIIT Research Institute · USKyiv International University · UAPharmalog (Germany) · DEBogomolets National Medical University · UAL.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Sciences of Ukraine · UAUniversity of Cambridge · GBZOZ Group (Germany) · DE

Funding

The regulatory functions of mini viral RNAs in influenza virus infectionsR21AI147172 · NIAID · UNIVERSITY OF CAMBRIDGE · PI IRIGOYEN, NEREA · 2019 to 2020
$231k
NIAID NIH HHS R21 AI147172Wellcome Trust
6 · The paper itself

Abstract

Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. Here we show that enisamium can inhibit SARS-CoV-2 infections in NHBE and Caco-2 cells.

Indexed as

AmizonCovid-19FAV00Amolecular dynamics simulationRNA polymeraseSARS-CoV-2

Identifiers

PMID33469600
PMCPMC7814846
OpenAlexW3118317614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.